

Francis Berenbaum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1558274/publications.pdf>

Version: 2024-02-01

346
papers

22,215
citations

11651

70
h-index

11308

136
g-index

378
all docs

378
docs citations

378
times ranked

22133
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis"™ by Singer et al. Annals of the Rheumatic Diseases, 2022, 81, e162-e162.	0.9	0
2	Response to: "Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues"™ by Riddle and Perera. Annals of the Rheumatic Diseases, 2022, 81, e66-e66.	0.9	0
3	General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care and Research, 2022, 74, 918-928.	3.4	5
4	Metacarpophalangeal Joint Impairment in Hand Osteoarthritis and Its Association With Mechanical Factors: Results From the Digital Cohort Osteoarthritis Design Hand Osteoarthritis Cohort. Arthritis Care and Research, 2022, 74, 1696-1703.	3.4	3
5	Intra-articular therapies: patient preferences and professional practices in European countries. Rheumatology International, 2022, 42, 869-878.	3.0	6
6	How the COVID-19 pandemic has affected rheumatology research. Nature Reviews Rheumatology, 2022, 18, 128-132.	8.0	0
7	Impact of carpal tunnel syndrome on symptoms and structural severity of hand osteoarthritis: results from the DIGICOD cohort. Clinical Rheumatology, 2022, 41, 947-950.	2.2	1
8	Statin use and MRI subchondral bone marrow lesion worsening in generalized osteoarthritis: longitudinal analysis from Osteoarthritis Initiative data. European Radiology, 2022, 32, 3944-3953.	4.5	6
9	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	3.9	30
10	What evidence is needed to demonstrate the beneficial effects of exercise for osteoarthritis?. Annals of the Rheumatic Diseases, 2022, 81, 451-453.	0.9	5
11	Development of radiographic classification criteria for hand osteoarthritis: a methodological report (Phase 2). RMD Open, 2022, 8, e002024.	3.8	5
12	The impact of COVID-19 on rheumatology training"™ results from the COVID-19 Global Rheumatology Alliance trainee survey. Rheumatology Advances in Practice, 2022, 6, rkac001.	0.7	7
13	Effect of Transcutaneous Vagus Nerve Stimulation in Erosive Hand Osteoarthritis: Results from a Pilot Trial. Journal of Clinical Medicine, 2022, 11, 1087.	2.4	15
14	Impact of Collagen Crosslinking on Dislocated Human Shoulder Capsules"™ Effect on Structural and Mechanical Properties. International Journal of Molecular Sciences, 2022, 23, 2297.	4.1	4
15	Gremlin-1 and BMP-4 Overexpressed in Osteoarthritis Drive an Osteochondral-Remodeling Program in Osteoblasts and Hypertrophic Chondrocytes. International Journal of Molecular Sciences, 2022, 23, 2084.	4.1	12
16	Use of machine learning in osteoarthritis research: a systematic literature review. RMD Open, 2022, 8, e001998.	3.8	23
17	Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination. Arthritis Research and Therapy, 2022, 24, 72.	3.5	0
18	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. Journal of Rheumatology, 2022, 49, 615-621.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Osteoarthritis endotype discovery via clustering of biochemical marker data. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 666-675.	0.9	51
20	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. <i>Rheumatology</i> , 2022, 61, SI143-SI150.	1.9	40
21	Alpha-7 Nicotinic Receptor Dampens Murine Osteoblastic Response to Inflammation and Age-Related Osteoarthritis. <i>Frontiers in Immunology</i> , 2022, 13, 842538.	4.8	5
22	2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1065-1071.	0.9	54
23	Transcutaneous vagus nerve stimulation in erosive hand osteoarthritis: protocol for the randomised, double-blind, sham-controlled ESTIVAL trial. <i>BMJ Open</i> , 2022, 12, e056169.	1.9	4
24	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	1.9	4
25	^{99m} Tc-NTP 15-5 is a companion radiotracer for assessing joint functional response to sprifermin (rhFGF-18) in a murine osteoarthritis model. <i>Scientific Reports</i> , 2022, 12, 8146.	3.3	1
26	The association of the lipid profile with knee and hand osteoarthritis severity: the IMI-APPROACH cohort. <i>Osteoarthritis and Cartilage</i> , 2022, 30, 1062-1069.	1.3	8
27	Pollutants: a candidate as a new risk factor for osteoarthritis—results from a systematic literature review. <i>RMD Open</i> , 2022, 8, e001983.	3.8	7
28	Time to Total Knee Arthroplasty after Intra-Articular Hyaluronic Acid or Platelet-Rich Plasma Injections: A Systematic Literature Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 3985.	2.4	5
29	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	5.6	52
30	Tackling osteoarthritis during COVID-19 pandemic. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 151-153.	0.9	14
31	Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: Results from the DESIR cohort. <i>Joint Bone Spine</i> , 2021, 88, 105068.	1.6	5
32	Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 475-486.	0.9	17
33	The differentiation of prehypertrophic into hypertrophic chondrocytes drives an OA-remodeling program and IL-34 expression. <i>Osteoarthritis and Cartilage</i> , 2021, 29, 257-268.	1.3	4
34	Role of adipose tissues in osteoarthritis. <i>Current Opinion in Rheumatology</i> , 2021, 33, 84-93.	4.3	21
35	Pain in women with knee and/or hip osteoarthritis is related to systemic inflammation and to adipose tissue dysfunction: Cross-sectional results of the KHOALA cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 129-136.	3.4	16
36	Vitamin K and osteoarthritis: is there a link?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 547-549.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus. <i>Molecules</i> , 2021, 26, 2593.	3.8	29
38	EULAR recommendations for intra-articular therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1299-1305.	0.9	42
39	Vagus nerve stimulation in musculoskeletal diseases. <i>Joint Bone Spine</i> , 2021, 88, 105149.	1.6	20
40	Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. <i>Rheumatology</i> , 2021, 60, 5073-5079.	1.9	12
41	Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?. <i>European Journal of Pain</i> , 2021, 25, 1525-1539.	2.8	9
42	Regulation of the acetylcholine/ α 7nAChR anti-inflammatory pathway in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 11886.	3.3	35
43	Osteoarthritis Research Society International (OARSI): Past, present and future. <i>Osteoarthritis and Cartilage Open</i> , 2021, 3, 100146.	2.0	1
44	Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. <i>RMD Open</i> , 2021, 7, e001658.	3.8	15
45	Metabolic Syndrome and Osteoarthritis Distribution in the Hand Joints: A Propensity Score Matching Analysis From the Osteoarthritis Initiative. <i>Journal of Rheumatology</i> , 2021, 48, 1608-1615.	2.0	8
46	The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis—methodology and baseline characteristics of the population. <i>Joint Bone Spine</i> , 2021, 88, 105171.	1.6	23
47	Efficacy of intra-articular corticosteroid injections in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. <i>Joint Bone Spine</i> , 2021, 88, 105198.	1.6	20
48	Hypertension meets osteoarthritis “revisiting the vascular aetiology hypothesis. <i>Nature Reviews Rheumatology</i> , 2021, 17, 533-549.	8.0	38
49	Baseline clinical characteristics of predicted structural and pain progressors in the IMI-APPROACH knee OA cohort. <i>RMD Open</i> , 2021, 7, e001759.	3.8	7
50	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-220549.	0.9	18
51	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. <i>RMD Open</i> , 2021, 7, e001814.	3.8	121
52	Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1311-1319.	3.4	6
53	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
54	Osteoarthritis and gut microbiome. <i>Joint Bone Spine</i> , 2021, 88, 105203.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Single and Composite Endpoints of Within-Patient Improvement in Symptoms: Pooled Tanezumab Data in Patients with Osteoarthritis. <i>Rheumatology and Therapy</i> , 2021, 8, 1759-1774.	2.3	3
56	Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. <i>International Journal of Clinical Practice</i> , 2021, 75, e14975.	1.7	2
57	Neuropathic pain in the IMI-APPROACH knee osteoarthritis cohort: prevalence and phenotyping. <i>RMD Open</i> , 2021, 7, e002025.	3.8	10
58	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 69-76.	0.9	55
59	Calprotectin alone is not sufficient to predict response to methotrexate in early ACR/EULAR 2010 rheumatoid arthritis: Analysis of the ESPOIR cohort. <i>Joint Bone Spine</i> , 2020, 87, 99-100.	1.6	2
60	Is hip osteoarthritis preventable?. <i>Joint Bone Spine</i> , 2020, 87, 371-375.	1.6	3
61	Development of a core capability framework for qualified health professionals to optimise care for people with osteoarthritis: an OARSI initiative. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 154-166.	1.3	31
62	Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis. <i>Joint Bone Spine</i> , 2020, 87, 548-555.	1.6	45
63	Recommandations de la Société française de rhumatologie sur la prise en charge pharmacologique de la gonarthrose. <i>Revue Du Rhumatisme (Edition Française)</i> , 2020, 87, 439-446.	0.0	4
64	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. <i>Annals of Internal Medicine</i> , 2020, 172, 819-821.	3.9	177
65	Cohort profile: The Applied Public-Private Research enabling OsteoArthritis Clinical Headway (IMI-APPROACH) study: a 2-year, European, cohort study to describe, validate and predict phenotypes of osteoarthritis using clinical, imaging and biochemical markers. <i>BMJ Open</i> , 2020, 10, e035101.	1.9	40
66	Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 800-810.	0.9	98
67	Clearing method for 3-dimensional immunofluorescence of osteoarthritic subchondral human bone reveals peripheral cholinergic nerves. <i>Scientific Reports</i> , 2020, 10, 8852.	3.3	15
68	Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. <i>Joint Bone Spine</i> , 2020, 87, 431-437.	1.6	20
69	Alternative and complementary therapies in osteoarthritis and cartilage repair. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 547-560.	2.9	65
70	The Role of the Non-Neuronal Cholinergic System in Inflammation and Degradation Processes in Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 2072-2082.	5.6	21
71	Development of classification criteria for hand osteoarthritis: comparative analyses of persons with and without hand osteoarthritis. <i>RMD Open</i> , 2020, 6, e001265.	3.8	14
72	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 659-666.	3.0	57

#	ARTICLE	IF	CITATIONS
73	Osteoarthritis and inflammation: a serious disease with overlapping phenotypic patterns. <i>Postgraduate Medicine</i> , 2020, 132, 377-384.	2.0	65
74	Osteoarthritis year in review 2019: epidemiology and therapy. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 242-248.	1.3	334
75	Association Between Vitamin D Deficiency and Disease Activity, Disability, and Radiographic Progression in Early Rheumatoid Arthritis: The ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 1624-1628.	2.0	18
76	<i>Festina lente</i>: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 734-736.	0.9	35
77	Needs, Experiences, and Views of People With Rheumatic and Musculoskeletal Diseases on Self-Management Mobile Health Apps: Mixed Methods Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e14351.	3.7	31
78	Novel Approach to Estimate Osteoarthritis Progression: Use of the Reliable Change Index in the Evaluation of Joint Space Loss. <i>Arthritis Care and Research</i> , 2019, 71, 300-307.	3.4	5
79	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). <i>Ageing Research Reviews</i> , 2019, 55, 100946.	10.9	103
80	La présence de diabète lors du diagnostic de la polyarthrite rhumatoïde est un facteur indépendant prédictif de mauvais résultats: données de la cohorte ESPOIR sur les polyarthrites récentes. <i>Revue Du Rhumatisme (Edition Française)</i> , 2019, 86, 534-536.	0.0	0
81	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. <i>RMD Open</i> , 2019, 5, e001004.	3.8	30
82	Cartilage-gut-microbiome axis: a new paradigm for novel therapeutic opportunities in osteoarthritis. <i>RMD Open</i> , 2019, 5, e001037.	3.8	56
83	Arthrose et diabète : pourquoi ? Les données fondamentales. <i>Medicine Des Maladies Metaboliques</i> , 2019, 13, 320-323.	0.1	0
84	Gait kinematics for patients with early stage knee osteoarthritis in the approach project. <i>Osteoarthritis and Cartilage</i> , 2019, 27, S114-S115.	1.3	0
85	14-3-3E, a new alarmin candidate, elicits a catabolic and proinflammatory effect involving innate immunity through TLR signaling in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2019, 27, S375-S376.	1.3	0
86	Priorities for the effective implementation of osteoarthritis management programs: an OARSI international consensus exercise. <i>Osteoarthritis and Cartilage</i> , 2019, 27, 1270-1279.	1.3	49
87	Recommendations of the French society of rheumatology for the pharmacological management of knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2019, 27, S507-S508.	1.3	2
88	Activating the cholinergic system a novel opportunity for treating osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2019, 27, S38.	1.3	2
89	The Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated Osteoarthritis. <i>Joint Bone Spine</i> , 2019, 86, 725-730.	1.6	83
90	THU0642â€¦EULAR POINTS TO CONSIDER FOR THE DEVELOPMENT, EVALUATION AND IMPLEMENTATION OF MOBILE HEALTH APPLICATIONS FOR SELF-MANAGEMENT IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	AB1350â€¦HOW TO REDUCE THE NOCEBO EFFECT IN RHEUMATOLOGY? A SYSTEMATIC REVIEW OF RISK FACTORS AND INTERVENTION STRATEGIES. , 2019, , .		0
92	FRI0100â€¦TOWARDS THE LOWEST EFFICACIOUS DOSE (TOLEDO): RESULTS OF A MULTICENTER NON-INFERIORITY RANDOMIZED OPEN-LABEL CONTROLLED TRIAL ASSESSING TOCILIZUMAB OR ABATACEPT INJECTION SPACING IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION. , 2019, , .		0
93	AB0104â€¦ARE POLLUTANTS A NEW RISK FACTOR FOR OSTEOARTHRITIS? RESULTS FROM A SYSTEMATIC LITERATURE REVIEW. , 2019, , .		0
94	SP0001â€¦WIN IN OA MANAGEMENT. , 2019, , .		0
95	LB0007â€¦SUBCUTANEOUS TANEZUMAB FOR OSTEOARTHRITIS PAIN: A 24-WEEK PHASE 3 STUDY WITH A 24-WEEK FOLLOW UP. , 2019, , .		0
96	Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open, 2019, 5, e000897.	3.8	17
97	The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open, 2019, 5, e001029.	3.8	20
98	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open, 2019, 5, e001014.	3.8	73
99	Intersite comparison and test-retest reliability of cartilage thickness and compositional analysis in the approach study â€œ a 2-year multicenter European exploratory study for phenotype characterization of knee osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, S326-S327.	1.3	1
100	Association between osteoarthritis and increased risk of dementia. Medicine (United States), 2019, 98, e14355.	1.0	49
101	Contribution of adipocyte precursors in the phenotypic specificity of intra-articular adipose tissues in knee osteoarthritis patients. Arthritis Research and Therapy, 2019, 21, 252.	3.5	4
102	Deep phenotyping of osteoarthritis: a step forward. Annals of the Rheumatic Diseases, 2019, 78, 3-5.	0.9	34
103	Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1Î± and anti-interleukin-1Î² dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 413-420.	0.9	115
104	Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases, 2019, 78, 209-217.	0.9	273
105	Report from the Hand Osteoarthritis Working Group at OMERACT 2018: Update on Core Instrument Set Development. Journal of Rheumatology, 2019, 46, 1183-1187.	2.0	10
106	A Phase II Trial of Lutikizumab, an Anti-Interleukin-1Î±/Î² Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis. Arthritis and Rheumatology, 2019, 71, 1056-1069.	5.6	137
107	Impairment of glyoxalase-1, an advanced glycation end-product detoxifying enzyme, induced by inflammation in age-related osteoarthritis. Arthritis Research and Therapy, 2019, 21, 18.	3.5	26
108	TGFÎ²i is involved in the chondrogenic differentiation of mesenchymal stem cells and is dysregulated in osteoarthritis. Osteoarthritis and Cartilage, 2019, 27, 493-503.	1.3	23

#	ARTICLE	IF	CITATIONS
109	Targeting nerve growth factor to relieve pain from osteoarthritis: What can we expect?. <i>Joint Bone Spine</i> , 2019, 86, 127-128.	1.6	10
110	Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review. <i>JMIR MHealth and UHealth</i> , 2019, 7, e14730.	3.7	70
111	Danger signals and inflammaging in osteoarthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 120, 48-56.	0.8	35
112	Challenges and Advances in Targeting Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 153-157.	2.0	12
113	Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort. <i>Joint Bone Spine</i> , 2018, 85, 773-775.	1.6	4
114	Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain. <i>Journal of Bone and Joint Surgery - Series A</i> , 2018, 100, 666-677.	3.0	120
115	e-Health, social media, and rheumatology: Can they get along?. <i>Joint Bone Spine</i> , 2018, 85, 265-266.	1.6	3
116	Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial. <i>Joint Bone Spine</i> , 2018, 85, 59-64.	1.6	15
117	Brief Report: A Phase III Trial of a Novel Extended-Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 204-211.	5.6	62
118	Poor efficacy of TNF inhibitors in non-radiographic axial spondyloarthritis in the absence of objective signs: A bicentric retrospective study. <i>Joint Bone Spine</i> , 2018, 85, 461-468.	1.6	11
119	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1399-1405.	1.3	21
120	Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 258-263.	0.9	16
121	Overview of osteo-articular involvement in systemic sclerosis: Specific risk factors, clinico-sonographic evaluation, and comparison with healthy women from the French OFELY cohort. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 591-604.	3.3	8
122	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. <i>BMJ Open</i> , 2018, 8, e021037.	1.9	17
123	Modern-day environmental factors in the pathogenesis of osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 674-681.	8.0	159
124	Increase In Il-31 Serum Levels Is Associated With Reduced Structural Damage In Early Axial Spondyloarthritis. <i>Scientific Reports</i> , 2018, 8, 7731.	3.3	17
125	Prehypertrophic to hypertrophic differentiation of chondrocytes induces IL-34 expression, a new cytokine with potential osteochondral junction remodeling activity in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2018, 26, S68-S69.	1.3	0
126	Implication of 14-3-3epsilon as a potential alarmin in bone/cartilage communication in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2018, 26, S62.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Development and application of a questionnaire to assess patient beliefs in rheumatoid arthritis and axial spondyloarthritis. <i>Clinical Rheumatology</i> , 2018, 37, 2649-2657.	2.2	13
128	SP0060â€¦Eular recommendations for the use of imaging in mechanical low back pain. , 2018, , .		0
129	â€Twitterlandâ€™: a brave new world?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212273. 0.9	0.9	7
130	Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 712-715.	0.9	48
131	Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. <i>RMD Open</i> , 2017, 3, e000344.	3.8	24
132	04.03â€¦Tgfb2-induced protein (tgfb2i) is dysregulated in osteoarthritis. , 2017, , .		0
133	Collecte et prise en charge de certaines comorbiditÃ©s et facteurs de risque associÃ©s dans le cadre des rhumatismes inflammatoires chroniques dans la pratique quotidienne en France. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 123-131.	0.0	0
134	Metabolic syndrome-associated osteoarthritis. <i>Current Opinion in Rheumatology</i> , 2017, 29, 214-222.	4.3	168
135	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. <i>Arthritis Research and Therapy</i> , 2017, 19, 115.	3.5	23
136	An intra-articular, extended release formulation of triamcinolone (FX006) affords clinically relevant improvements in pain and function of knee osteoarthritis: post-hoc pooled analyses of 3 randomized controlled trials. <i>Osteoarthritis and Cartilage</i> , 2017, 25, S432-S433.	1.3	3
137	Effet de lâ€™Ã¢ge dâ€™apparition de la polyarthrite rhumatoÃ¯de sur lâ€™Ã©volution clinique, radiographique et fonctionnelle: la cohorte ESPOIR. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 498-503.	0.0	0
138	Knee and hip intra-articular adipose tissues (IAATs) compared with autologous subcutaneous adipose tissue: a specific phenotype for a central player in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1142-1148.	0.9	78
139	Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. <i>Clinical Rheumatology</i> , 2017, 36, 485-497.	2.2	25
140	Cardiometabolic risk factors in primary centred and rotator cuff-related shoulder osteoarthritis: a comparative study. <i>RMD Open</i> , 2017, 3, e000429.	3.8	4
141	Evolution of pain at 3 months by oral resveratrol in knee osteoarthritis (ARTHROL): protocol for a multicentre randomised double-blind placebo-controlled trial. <i>BMJ Open</i> , 2017, 7, e017652.	1.9	14
142	Association between osteoarthritis and dyslipidaemia: a systematic literature review and meta-analysis. <i>RMD Open</i> , 2017, 3, e000442.	3.8	57
143	Investigating the role of panx3 in mechanostimulation and pro-inflammatory responses in chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2017, 25, S150-S151.	1.3	0
144	The French Patient's Association (Aflar: French League Against Rheumatism) has Generated The French National Alliance Against Osteoarthritis and the First General Convention of Osteoarthritis in France: A Campaign to Create a National Lobbying Tool to Improve the Management of Osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2017, 25, S221-S222.	1.3	0

#	ARTICLE	IF	CITATIONS
145	TGFb-induced Protein is Dysregulated in Osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2017, 25, S325-S326.	1.3	1
146	The nuclear factor-erythroid 2-related factor/heme oxygenase-1 axis is critical for the inflammatory features of type 2 diabetes-associated osteoarthritis. <i>Journal of Biological Chemistry</i> , 2017, 292, 14505-14515.	3.4	41
147	Reduction of the Serum Levels of a Specific Biomarker of Cartilage Degradation (Coll2-1) by Hyaluronic Acid (KARTILAGE [®] CROSS) Compared to Placebo in Painful Knee Osteoarthritis Patients: the EPIKART Study, a Pilot Prospective Comparative Randomized Double Blind Trial. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 222.	1.9	24
148	Review: Metabolic Regulation of Inflammation in Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 9-21.	5.6	164
149	08.26...The prevalence of acpa is lower in rheumatoid arthritis patients with a higher age of onset but the composition of the acpa response appears identical. , 2017, , .		0
150	Role of the autonomic nervous system in osteoarthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 661-675.	3.3	30
151	Osteoarthritis: Research in motion. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 611-612.	3.3	1
152	French law: what about a reasoned reimbursement of serum vitamin D assays?. <i>Psychologie & Neuropsychiatrie Du Vieillissement</i> , 2016, 14, 377-382.	0.2	7
153	Collection and management of selected comorbidities and their risk factors in chronic inflammatory rheumatic diseases in daily practice in France. <i>Joint Bone Spine</i> , 2016, 83, 501-509.	1.6	39
154	Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2101-2107.	0.9	38
155	Translation of clinical problems in osteoarthritis into pathophysiological research goals. <i>RMD Open</i> , 2016, 2, e000224.	3.8	16
156	High Levels Of Fears Of Patients With Rheumatoid Arthritis Or Axial Spondyloarthritis Are Associated With Gender, Disease Activity, Anxiety And Depression: A Cross-Sectional Study Of 672 Patients. <i>Value in Health</i> , 2016, 19, A473-A474.	0.3	0
157	Knee and hip intra-articular adipose tissues share a common phenotype in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2016, 24, S339.	1.3	0
158	Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France. <i>Journal of Medical Economics</i> , 2016, 19, 812-821.	2.1	9
159	Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. <i>Skeletal Radiology</i> , 2016, 45, 1495-1506.	2.0	21
160	The danger from within: alarmins in arthritis. <i>Nature Reviews Rheumatology</i> , 2016, 12, 669-683.	8.0	111
161	Body mass index and response to abatacept in rheumatoid arthritis. <i>European Journal of Clinical Investigation</i> , 2016, 46, 1048-1052.	3.4	26
162	Response to: "Does the prevalence of radiographic hand osteoarthritis in patients with HIV-1 infection increase or not?" by Luo et al. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e52-e52.	0.9	0

#	ARTICLE	IF	CITATIONS
163	Sustained and profound analgesic benefits in people with osteoarthritis of the knee using FX006, an intra-articular extended-release formulation of triamcinolone acetonide: Results from a double-blind, randomized, parallel-group, dose-ranging study. <i>Osteoarthritis and Cartilage</i> , 2016, 24, S49-S50.	1.3	2
164	The brainâ€‘joint axis in osteoarthritis: nerves, circadian clocks and beyond. <i>Nature Reviews Rheumatology</i> , 2016, 12, 508-516.	8.0	53
165	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 37-44.	0.9	194
166	Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. <i>Clinical Rheumatology</i> , 2016, 35, 857-861.	2.2	38
167	Effect of age at rheumatoid arthritis onset on clinical, radiographic, and functional outcomes: The ESPOIR cohort. <i>Joint Bone Spine</i> , 2016, 83, 511-515.	1.6	38
168	Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?. <i>Scandinavian Journal of Rheumatology</i> , 2016, 45, 87-98.	1.1	48
169	Does platelet-rich plasma have a role in the treatment of osteoarthritis?. <i>Joint Bone Spine</i> , 2016, 83, 31-36.	1.6	74
170	Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0145076.	2.5	42
171	Metabolic stress-induced joint inflammation and osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 1955-1965.	1.3	160
172	Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 843-850.	0.9	86
173	The pro-inflammatory cytokine s14-3-3 μ is a ligand of CD13/Aminopeptidase N in cartilage. <i>Journal of Cell Science</i> , 2015, 128, 3250-62.	2.0	23
174	Fatigue in chronic inflammation - a link to pain pathways. <i>Arthritis Research and Therapy</i> , 2015, 17, 254.	3.5	135
175	Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts. <i>RMD Open</i> , 2015, 1, e000128.	3.8	17
176	Commentary on recent therapeutic guidelines for osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 611-617.	3.4	88
177	AA amyloidosis treated with tocilizumab: case series and updated literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 84-92.	3.0	37
178	Quelle place pour les PRP (plasma riche en plaquettes) dans les tendinopathies? <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 80-84.	0.0	0
179	Tendon injury: from biology to tendon repair. <i>Nature Reviews Rheumatology</i> , 2015, 11, 223-233.	8.0	335
180	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Epidemiology and Phenotype of Osteoarthritis. <i>Drugs and Aging</i> , 2015, 32, 179-187.	2.7	82

#	ARTICLE	IF	CITATIONS
181	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	2.7	31
182	Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 2086-2093.	1.3	47
183	Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort. <i>Joint Bone Spine</i> , 2015, 82, 345-351.	1.6	92
184	Association between diabetes mellitus and osteoarthritis: systematic literature review and meta-analysis. <i>RMD Open</i> , 2015, 1, e000077-e000077.	3.8	235
185	Cartilage in the context of hyperglycemia and diabetes: Further pathophysiological clues for diabetes-related osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2015, 23, A293.	1.3	2
186	Critical role of CD13/aminopeptidase N in bone/cartilage communication in osteoarthritis: Ability to bind 14-3-3E. <i>Osteoarthritis and Cartilage</i> , 2015, 23, A161.	1.3	0
187	Cardiometabolic disturbances and hand osteoarthritis: A cross-sectional and longitudinal study. <i>Osteoarthritis and Cartilage</i> , 2015, 23, A53.	1.3	1
188	Intra-articular injections in thumb osteoarthritis: A systematic review and meta-analysis of randomized controlled trials. <i>Joint Bone Spine</i> , 2015, 82, 315-319.	1.6	41
189	Emerging targets in osteoarthritis therapy. <i>Current Opinion in Pharmacology</i> , 2015, 22, 51-63.	3.5	142
190	Does platelet-rich plasma deserve a role in the treatment of tendinopathy?. <i>Joint Bone Spine</i> , 2015, 82, 230-234.	1.6	25
191	Présentation clinique des patients souffrant de rachialgie inflammatoire chronique récente Â©vocatrice de spondyloarthrite: la cohorte Desir. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2015, 82, 378-385.	0.0	0
192	Inflammation in osteoarthritis: changing views. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 1823-1824.	1.3	24
193	Differential expression of interleukin-17 and interleukin-22 in inflamed and non-inflamed synovium from osteoarthritis patients. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 1843-1852.	1.3	80
194	Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1725-1733.	0.9	130
195	Characterization of diabetic osteoarthritic cartilage and role of high glucose environment on chondrocyte activation: toward pathophysiological delineation of diabetes mellitus-related osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2015, 23, 1513-1522.	1.3	91
196	Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort. <i>PLoS ONE</i> , 2015, 10, e0134974.	2.5	26
197	Fears and Beliefs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Study. <i>PLoS ONE</i> , 2014, 9, e114350.	2.5	39
198	The social (media) side to rheumatology. <i>Nature Reviews Rheumatology</i> , 2014, 10, 314-318.	8.0	24

#	ARTICLE	IF	CITATIONS
199	Reporting of patient-perceived impact of rheumatoid arthritis and axial spondyloarthritis over 10 years: a systematic literature review. <i>Rheumatology</i> , 2014, 53, 1274-1281.	1.9	22
200	Work Productivity Loss in Early Arthritis During the First 3 Years of Disease: A Study From a French National Multicenter Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1310-1318.	3.4	8
201	Induction of an Inflammatory and Prodegradative Phenotype in Autologous Fibroblast-Like Synoviocytes by the Infrapatellar Fat Pad From Patients With Knee Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2165-2174.	5.6	104
202	Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes. <i>Arthritis Research and Therapy</i> , 2014, 16, R137.	3.5	20
203	Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. <i>Arthritis Research and Therapy</i> , 2014, 16, 481.	3.5	27
204	Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 154.	5.2	68
205	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 271-282.	3.4	29
206	Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain. <i>Arthritis Research and Therapy</i> , 2014, 16, R16.	3.5	96
207	Rhumatisme fibroblastique: le traitement immunosuppresseur n'est pas toujours requis. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014, 81, 185-187.	0.0	0
208	Response to Letter to the Editor entitled "Comments on OARSI guidelines for the non-surgical management of knee osteoarthritis". <i>Osteoarthritis and Cartilage</i> , 2014, 22, 890-891.	1.3	15
209	Infrapatellar fat pad induces an inflammatory and catabolic phenotype on autologous fibroblast-like synoviocytes from severe knee oa patients. <i>Osteoarthritis and Cartilage</i> , 2014, 22, S448.	1.3	1
210	Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R38.	3.5	88
211	OARSI guidelines for the non-surgical management of knee osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 363-388.	1.3	2,298
212	Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 1800-1807.	1.3	48
213	Potential Role of Hyaluronic Acid on Bone in Osteoarthritis: Matrix Metalloproteinases, Aggrecanases, and RANKL Expression are Partially Prevented by Hyaluronic Acid in Interleukin 1-stimulated Osteoblasts. <i>Journal of Rheumatology</i> , 2014, 41, 945-954.	2.0	25
214	Does broccoli protect from osteoarthritis?. <i>Joint Bone Spine</i> , 2014, 81, 284-286.	1.6	9
215	Response to "Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort" authors' reply. <i>Arthritis Research and Therapy</i> , 2014, 16, 408.	3.5	1
216	What happens to Kellgren-Lawrence grade 1 joints in hand osteoarthritis (OA) after 2.6 years? OA or not OA that is the question? Data from the SEKOIA trial. <i>Osteoarthritis and Cartilage</i> , 2014, 22, S270.	1.3	0

#	ARTICLE	IF	CITATIONS
217	Fibroblastic rheumatism: Immunosuppressive therapy is not always required. <i>Joint Bone Spine</i> , 2014, 81, 178-179.	1.6	6
218	Secreted 14-3-3 μ : discovery by proteomics of a novel biomarker and/or therapeutical target in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2013, 21, S225-S226.	1.3	0
219	Homeostatic Mechanisms in Articular Cartilage and Role of Inflammation in Osteoarthritis. <i>Current Rheumatology Reports</i> , 2013, 15, 375.	4.7	259
220	Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 312-314.	0.9	13
221	Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. <i>Arthritis Research and Therapy</i> , 2013, 15, R210.	3.5	64
222	Editorial: Osteoarthritis: When Chondrocytes Don't Wake Up on Time. <i>Arthritis and Rheumatism</i> , 2013, 65, 2233-2235.	6.7	7
223	How to define responders in osteoarthritis. <i>Current Medical Research and Opinion</i> , 2013, 29, 719-729.	1.9	75
224	Diabetes Is an Independent Predictor for Severe Osteoarthritis. <i>Diabetes Care</i> , 2013, 36, 403-409.	8.6	270
225	Is osteoarthritis a metabolic disease?. <i>Joint Bone Spine</i> , 2013, 80, 568-573.	1.6	220
226	Is radiographic knee osteoarthritis more severe when hand osteoarthritis is present and conversely? A cross-sectional study in 1371 knee osteoarthritis patients. <i>Osteoarthritis and Cartilage</i> , 2013, 21, S246.	1.3	1
227	Clinical image: Spondylodiscitis due to a fistula between L5-S1 disc and colon. <i>Joint Bone Spine</i> , 2013, 80, 100-101.	1.6	0
228	Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). <i>Osteoarthritis and Cartilage</i> , 2013, 21, 16-21.	1.3	1,197
229	Identification of Soluble 14-3-3 μ as a Novel Subchondral Bone Mediator Involved in Cartilage Degradation in Osteoarthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 1831-1842.	6.7	54
230	Osteoarthritis, inflammation and obesity. <i>Current Opinion in Rheumatology</i> , 2013, 25, 114-118.	4.3	212
231	Potential Classification Criteria for Rheumatoid Arthritis After Two Years: Results From a French Multicenter Cohort. <i>Arthritis Care and Research</i> , 2013, 65, 1227-1234.	3.4	16
232	Kinetic Profiles and Management of Hepatitis B Virus Reactivation in Patients With Immune-Mediated Inflammatory Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1504-1514.	3.4	43
233	Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort. <i>Journal of Rheumatology</i> , 2013, 40, 1650-1657.	2.0	38
234	Use of autologous growth factors in aging tendon and chronic tendinopathy. <i>Frontiers in Bioscience - Elite</i> , 2013, E5, 911-921.	1.8	20

#	ARTICLE	IF	CITATIONS
235	Transcription factor EGR1 directs tendon differentiation and promotes tendon repair. <i>Journal of Clinical Investigation</i> , 2013, 123, 3564-3576.	8.2	201
236	Let's Talk about OA Pain: A Qualitative Analysis of the Perceptions of People Suffering from OA. Towards the Development of a Specific Pain OA-Related Questionnaire, the Osteoarthritis Symptom Inventory Scale (OASIS). <i>PLoS ONE</i> , 2013, 8, e79988.	2.5	42
237	Assessment and determinants of aesthetic discomfort in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 45-49.	0.9	34
238	A randomised, double-blind, controlled trial comparing two intra-articular hyaluronic acid preparations differing by their molecular weight in symptomatic knee osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1454-1460.	0.9	111
239	Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. <i>Postgraduate Medical Journal</i> , 2012, 88, 240-242.	1.8	43
240	Proinflammatory Actions of Visfatin/Nicotinamide Phosphoribosyltransferase (Nampt) Involve Regulation of Insulin Signaling Pathway and Nampt Enzymatic Activity. <i>Journal of Biological Chemistry</i> , 2012, 287, 15100-15108.	3.4	56
241	Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. <i>Rheumatology</i> , 2012, 51, 60-68.	1.9	95
242	Stress-induced cartilage degradation does not depend on the NLRP3 inflammasome in human osteoarthritis and mouse models. <i>Arthritis and Rheumatism</i> , 2012, 64, 3972-3981.	6.7	59
243	Induction of the chemokine IL-8/Kc by the articular cartilage: Possible influence on osteoarthritis. <i>Joint Bone Spine</i> , 2012, 79, 604-609.	1.6	58
244	Rituximab Treatment for Spondyloarthritis. A Nationwide Series: Data from the AIR Registry of the French Society of Rheumatology. <i>Journal of Rheumatology</i> , 2012, 39, 2327-2331.	2.0	50
245	Induction de la chimiokine IL-8/Kc par le cartilage: le potentiel dans l'arthrose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2012, 79, 412-417.	0.0	0
246	A potential role of chondroitin sulfate on bone in osteoarthritis: inhibition of prostaglandin E2 and matrix metalloproteinases synthesis in interleukin-1 β -stimulated osteoblasts. <i>Osteoarthritis and Cartilage</i> , 2012, 20, 127-135.	1.3	51
247	Paper # 219: Cell Therapies Enhance Bone Tendon Healing in a Degenerative Model of Enthesis Lesion. <i>Arthroscopy - Journal of Arthroscopic and Related Surgery</i> , 2011, 27, e216-e217.	2.7	0
248	Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: A Multiple-treatment Bayesian Metaanalysis. <i>Journal of Rheumatology</i> , 2011, 38, 835-845.	2.0	45
249	Osteoarthritis: an update with relevance for clinical practice. <i>Lancet</i> , The, 2011, 377, 2115-2126.	13.7	1,705
250	Introduction to OARSI FDA initiative OAC special edition. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 475-477.	1.3	13
251	Osteoarthritis year 2010 in review: pharmacological therapies. <i>Osteoarthritis and Cartilage</i> , 2011, 19, 361-365.	1.3	43
252	The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients. <i>Joint Bone Spine</i> , 2011, 78, 598-603.	1.6	204

#	ARTICLE	IF	CITATIONS
253	Crusted Norwegian scabies, an opportunistic infection, with tocilizumab in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2011, 78, 402-404.	1.6	17
254	Gale croûteuse norvégienne, une infection opportuniste, survenant sous tocilizumab dans le traitement de la polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2011, 78, 382-384.	0.0	0
255	Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1354-1356.	0.9	146
256	Reliability, sensitivity to change and feasibility of three radiographic scoring methods for hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1465-1467.	0.9	22
257	Bone mineral density and joint cartilage: four clinical settings of a complex relationship in osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1523-1525.	0.9	47
258	The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 818-822.	0.9	72
259	Assessing health-related quality of life in hand osteoarthritis: a literature review. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 921-928.	0.9	93
260	Généralité des maladies du cartilage (arthrose, chondrodysplasies). <i>Revue Du Rhumatisme Monographies</i> , 2010, 77, 321-327.	0.0	0
261	433 IMPROVEMENT OF THE REPRODUCIBILITY OF THE RADIOGRAPHIC KELLGREN-LAWRENCE (KL) SCORING SYSTEM IN HAND OSTEOARTHRITIS (HOA) USING A NEW KL SCORING SYSTEM AID. <i>Osteoarthritis and Cartilage</i> , 2010, 18, S193-S194.	1.3	0
262	Stigmasterol: a phytosterol with potential anti-osteoarthritic properties. <i>Osteoarthritis and Cartilage</i> , 2010, 18, 106-116.	1.3	269
263	Targeted therapies in osteoarthritis: a systematic review of the trials on www.clinicaltrials.gov . <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 107-119.	3.3	20
264	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 1-2.	3.3	7
265	Is sarcoma a complication of arterial femoro-popliteal bypass?. <i>Joint Bone Spine</i> , 2010, 77, 358-360.	1.6	13
266	Le sarcome est-il une complication du pontage artériel fémoro-poplitéal?. <i>Revue Du Rhumatisme (Edition)</i> 0.0 0.0 rgBT /Ove	0.0	0
267	Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. <i>Rheumatology</i> , 2010, 49, 147-155.	1.9	31
268	Inhibition of Matrix Metalloproteinase-3 and -13 Synthesis Induced by IL-1 β in Chondrocytes from Mice Lacking Microsomal Prostaglandin E Synthase-1. <i>Journal of Immunology</i> , 2010, 185, 6244-6252.	0.8	31
269	Management of Osteoarthritis. , 2010, , 303-316.		0
270	The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2010, 6, 625-635.	8.0	1,029

#	ARTICLE	IF	CITATIONS
271	Mesenchymal Stem Cell Therapy Regenerates the Native Bone-Tendon Junction after Surgical Repair in a Degenerative Rat Model. PLoS ONE, 2010, 5, e12248.	2.5	111
272	Predictive Factors of Eczema-Like Eruptions among Patients without Cutaneous Psoriasis Receiving Infliximab: A Cohort Study of 92 Patients. Dermatology, 2009, 219, 263-267.	2.1	41
273	Time for new outcome measures in hand osteoarthritis?. Nature Reviews Rheumatology, 2009, 5, 136-138.	8.0	13
274	Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts. Osteoarthritis and Cartilage, 2009, 17, 473-481.	1.3	123
275	Proteomics: addressing the challenges of osteoarthritis. Drug Discovery Today, 2009, 14, 661-667.	6.4	14
276	Involvement of the notch pathway in the regulation of matrix metalloproteinase 13 and the dedifferentiation of articular chondrocytes in murine cartilage. Arthritis and Rheumatism, 2009, 60, 428-439.	6.7	37
277	Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology, 2009, 48, 1429-1434.	1.9	106
278	Adipokines in Arthritis: New Kids on the Block. Current Rheumatology Reviews, 2009, 5, 226-232.	0.8	17
279	Arthrose et obésité: modèles expérimentaux. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 1215-1219.	0.0	1
280	Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E ₂ synthesis in chondrocytes: Possible influence on osteoarthritis. Arthritis and Rheumatism, 2008, 58, 1399-1409.	6.7	179
281	Primary culture and phenotyping of murine chondrocytes. Nature Protocols, 2008, 3, 1253-1260.	12.0	567
282	Obesity and osteoarthritis: what are the links?. Joint Bone Spine, 2008, 75, 667-668.	1.6	38
283	Osteoarthritis and obesity: Experimental models. Joint Bone Spine, 2008, 75, 675-679.	1.6	89
284	Stress-induced signaling pathways in hyalin chondrocytes: inhibition by Avocado-Soybean Unsaponifiables (ASU). Osteoarthritis and Cartilage, 2008, 16, 373-384.	1.3	57
285	New horizons and perspectives in the treatment of osteoarthritis. Arthritis Research and Therapy, 2008, 10, S1.	3.5	61
286	Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs. American Journal of Medicine, 2008, 121, 464-474.	1.5	81
287	Osteoblast: A cell under compression. Bio-Medical Materials and Engineering, 2008, 18, 221-224.	0.6	0
288	Mechanical stress and prostaglandin E ₂ synthesis in cartilage. Biorheology, 2008, 45, 301-320.	0.4	41

#	ARTICLE	IF	CITATIONS
289	Mechanical stress and prostaglandin E2 synthesis in cartilage. <i>Biorheology</i> , 2008, 45, 301-20.	0.4	18
290	Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1610-1615.	0.9	80
291	c-Fos immunoreactivity induced by intraperitoneal LPS administration is reduced in the brain of mice lacking the microsomal prostaglandin E synthase-1 (mPGES-1). <i>Brain, Behavior, and Immunity</i> , 2007, 21, 1109-1121.	4.1	41
292	The quest for the Holy Grail: a disease-modifying osteoarthritis drug. <i>Arthritis Research and Therapy</i> , 2007, 9, 111.	3.5	15
293	Lumiracoxib in the management of osteoarthritis and acute pain. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1551-1564.	1.8	23
294	Potentialisation de fluindione et warfarine par dexaméthasone dans le myélome multiple et l'amylose AL. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 845-851.	0.0	0
295	Inflammation et pathologies articulaires. <i>Revue Francophone Des Laboratoires</i> , 2007, 2007, 37-42.	0.0	0
296	Use of infliximab to treat psoriatic arthritis in HIV-positive patients. <i>Joint Bone Spine</i> , 2007, 74, 197-200.	1.6	70
297	Potentialisation de fluindione ou warfarin by dexamethasone in multiple myeloma and AL amyloidosis. <i>Joint Bone Spine</i> , 2007, 74, 446-452.	1.6	18
298	The ESPOIR cohort: A ten-year follow-up of early arthritis in France. <i>Joint Bone Spine</i> , 2007, 74, 440-445.	1.6	161
299	HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 138-146.	1.3	36
300	Coxibs and NSAIDs – Is the air any clearer? Perspectives from the OARSI/International COX-2 Study Group Workshop 2007. <i>Osteoarthritis and Cartilage</i> , 2007, 15, 849-856.	1.3	13
301	Utilisation de l'infliximab dans le traitement du rhumatisme psoriasique au cours de l'infection par le virus de l'immunodéficience humaine (VIH). <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 297-300.	0.0	0
302	Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. <i>Arthritis Research and Therapy</i> , 2006, 8, R114.	3.5	106
303	Prostaglandin E2 synthesis in cartilage explants under compression: mPGES-1 is a mechanosensitive gene. <i>Arthritis Research and Therapy</i> , 2006, 8, R135.	3.5	81
304	The Role of IL-1 and IL-1Ra in Joint Inflammation and Cartilage Degradation. <i>Vitamins and Hormones</i> , 2006, 74, 371-403.	1.7	161
305	Obesity and osteoarthritis: more complex than predicted!. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1403-1405.	0.9	281
306	Involvement of central microsomal prostaglandin E synthase-1 in IL-1 β -induced anorexia. <i>Physiological Genomics</i> , 2006, 25, 485-492.	2.3	46

#	ARTICLE	IF	CITATIONS
307	Cartilage breakdown in rheumatoid arthritis. <i>Joint Bone Spine</i> , 2006, 73, 29-36.	1.6	87
308	Muscle involvement in sarcoidosis: a retrospective and followup studies. <i>Journal of Rheumatology</i> , 2006, 33, 98-103.	2.0	62
309	New Target Genes for NOV/CCN3 in Chondrocytes: TGF- β 2 and Type X Collagen. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 2213-2223.	2.8	34
310	VIOXX and cardiovascular events: a class effect?. <i>Joint Bone Spine</i> , 2005, 72, 1-3.	1.6	40
311	Immature murine articular chondrocytes in primary culture: a new tool for investigating cartilage. <i>Osteoarthritis and Cartilage</i> , 2005, 13, 243-249.	1.3	69
312	Coxibs and NSAIDs “clearing the air. <i>Osteoarthritis and Cartilage</i> , 2005, 13, 545-547.	1.3	6
313	Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 521-533.	4.1	31
314	Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine Studies. <i>Journal of International Medical Research</i> , 2005, 33, 21-41.	1.0	32
315	Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1419-1426.	0.9	71
316	COX-3: Fact or fancy?. <i>Joint Bone Spine</i> , 2004, 71, 451-453.	1.6	21
317	Signal transduction pathways: new targets for treating rheumatoid arthritis. <i>Joint Bone Spine</i> , 2004, 71, 503-510.	1.6	67
318	Up-regulation of microsomal prostaglandin E synthase 1 in osteoarthritic human cartilage: Critical roles of the ERK-1/2 and p38 signaling pathways. <i>Arthritis and Rheumatism</i> , 2004, 50, 2829-2838.	6.7	124
319	Culture and Phenotyping of Chondrocytes in Primary Culture. , 2004, 100, 001-014.		70
320	Signaling transduction: target in osteoarthritis. <i>Current Opinion in Rheumatology</i> , 2004, 16, 616-622.	4.3	119
321	The Regulation of Chondrocyte Function by Proinflammatory Mediators. <i>Clinical Orthopaedics and Related Research</i> , 2004, 427, S37-S46.	1.5	222
322	NSAIDs and aspirin: friends or foes?. <i>Joint Bone Spine</i> , 2003, 70, 89-90.	1.6	5
323	Anti-tumor necrosis factor γ therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: A followup report of tolerability and efficacy. <i>Arthritis and Rheumatism</i> , 2003, 48, 2019-2024.	6.7	204
324	Concomitant Recruitment of ERK1/2 and p38 MAPK Signalling Pathway Is Required for Activation of Cytoplasmic Phospholipase A2 via ATP in Articular Chondrocytes. <i>Journal of Biological Chemistry</i> , 2003, 278, 13680-13687.	3.4	80

#	ARTICLE	IF	CITATIONS
325	Differentiation regulates interleukin-1 β -induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase. <i>Biochemical Journal</i> , 2002, 362, 367.	3.7	56
326	Differentiation regulates interleukin-1 β -induced cyclo-oxygenase-2 in human articular chondrocytes: role of p38 mitogen-activated protein kinase. <i>Biochemical Journal</i> , 2002, 362, 367-373.	3.7	65
327	Design of a chimeric promoter induced by pro-inflammatory mediators in articular chondrocytes. <i>FEBS Letters</i> , 2002, 518, 67-71.	2.8	4
328	Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. <i>Joint Bone Spine</i> , 2002, 69, 195-200.	1.6	24
329	Blood ferritin and iso-ferritins measurements may be helpful in acute respiratory distress syndrome patients. <i>Intensive Care Medicine</i> , 2002, 28, 998-998.	8.2	2
330	Chronic use of non-steroidal anti-inflammatory drugs does not alter colonic mucosa of patients without diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1301-1306.	3.7	7
331	Immortalized human adult articular chondrocytes maintain cartilage-specific phenotype and responses to interleukin-1 β . <i>Arthritis and Rheumatism</i> , 2000, 43, 2189-2201.	6.7	114
332	Critical role of C/EBP β and C/EBP δ factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1 β in articular chondrocytes. <i>FEBS Journal</i> , 2000, 267, 6798-6809.	0.2	105
333	Mise en évidence d'une réaction inflammatoire systémique par dosage de la protéine C-réactive plasmatique au cours de la lombosciatique par hernie discale. <i>Revue Du Rhumatisme (Edition) Tj ETQq1 1 0.784314rgBT /Overlock 10</i>		
334	Anatomopathologie et pathogénie de l'arthrose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2000, 67, 119-125.	0.0	12
335	Proinflammatory cytokines, prostaglandins, and the chondrocyte: mechanisms of intracellular activation. <i>Joint Bone Spine</i> , 2000, 67, 561-564.	1.6	50
336	Selective cyclooxygenase-2 inhibitors: hope and facts. <i>Joint Bone Spine</i> , 2000, 67, 499-501.	1.6	6
337	Induction of Secreted Type IIA Phospholipase A2 Gene Transcription by Interleukin-1 β . <i>Journal of Biological Chemistry</i> , 2000, 275, 22686-22694.	3.4	52
338	Transcriptional regulation of inflammatory secreted phospholipases A2. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2000, 1488, 149-158.	2.4	56
339	Critical role of C/EBP δ and C/EBP β factors in the stimulation of the cyclooxygenase-2 gene transcription by interleukin-1 β in articular chondrocytes. <i>FEBS Journal</i> , 2000, 267, 6798-6809.	0.2	2
340	Human chondrocyte culture models for studying cyclooxygenase expression and prostaglandin regulation of collagen gene expression. <i>Osteoarthritis and Cartilage</i> , 1999, 7, 386-388.	1.3	44
341	Group B Streptococcal Vertebral Osteomyelitis with Bacteraemia in an Adult with no Debilitating Condition. <i>Scandinavian Journal of Infectious Diseases</i> , 1999, 31, 316-317.	1.5	10
342	Posttranscriptional effect of insulin-like growth factor-I on interleukin-1 β -induced type II-secreted phospholipase A2 gene expression in rabbit articular chondrocytes. <i>Journal of Clinical Investigation</i> , 1997, 99, 1864-1872.	8.2	42

#	ARTICLE	IF	CITATIONS
343	Synergistic Effect of Interleukin-1 ^β and Tumor Necrosis Factor α on PGE ₂ Production by Articular Chondrocytes Does Not Involve PLA ₂ Stimulation. <i>Experimental Cell Research</i> , 1996, 222, 379-384.	2.6	75
344	Insulin-like growth factors counteract the effect of interleukin 1 ^β on type II phospholipase A ₂ expression and arachidonic acid release by rabbit articular chondrocytes. <i>FEBS Letters</i> , 1994, 340, 51-55.	2.8	29
345	Epidural Lipomatosis. <i>Spine</i> , 1994, 19, 251-254.	2.0	57
346	Interleukin-1-Induced Prostaglandin E ₂ Biosynthesis in Human Synovial Cells Involves the Activation of Cytosolic Phospholipase A ₂ and Cyclooxygenase-2. <i>FEBS Journal</i> , 1994, 226, 125-131.	0.2	94